SCHEMBL30775415

SCHEMBL30775415

Fc1cncnc1N1CCOCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.58
GAA P10253 1/20 0.49
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PTK2 Q05397 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LRRK2 Q5S007 8/20 0.45
STK4 Q13043 2/20 0.45
STK3 Q13188 2/20 0.45
CHEK1 O14757 1/20 0.44
PDPK1 O15530 1/20 0.44
MAPK1 P28482 1/20 0.44
PAK1 Q13153 1/20 0.44
JAK3 P52333 1/20 0.43
MAP4K4 O95819 1/20 0.43
PIK3CA P42336 1/20 0.43
ADK P55263 1/20 0.42
KDM5A P29375 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17364448 1.00 KDM4E (0.58) KDM4EGAAMEN1KMT2APTK2
SCHEMBL30775228 0.83 TP53 (0.40) KDM4EGAAMEN1KMT2ANPC1
SCHEMBL30775322 0.81 TP53 (0.42) KDM4EMEN1KMT2ANPC1RAB9A
SCHEMBL10435174 0.80 CYP2D6 (0.39) KDM4EGAAMEN1KMT2ASMN1; SMN2
SCHEMBL30775194 0.79 SMN1; SMN2 (0.57) MEN1KMT2ASMN1; SMN2MAPK1
SCHEMBL30775287 0.79 HSD17B10 (0.42) KDM4EGAAMEN1KMT2ASMN1; SMN2
SCHEMBL16646727 0.79 MEN1 (0.49) KDM4EGAAMEN1KMT2APTK2
SCHEMBL27498193 0.79 MAPK1 (0.54) KDM4EGAAMEN1KMT2APTK2
SCHEMBL16702828 0.79 KDM4E (0.57) KDM4EGAAMEN1KMT2APTK2
SCHEMBL359478 0.79 KDM4E (0.49) KDM4EGAAMEN1KMT2APTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR KDM4E 4591/4885GAA 81/4885MEN1 1984/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR KDM4E 4591/4885GAA 81/4885MEN1 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.